Unilateral primary aldosteronism as an independent risk factor for vertebral fracture
- PMID: 31868939
- DOI: 10.1111/cen.14145
Unilateral primary aldosteronism as an independent risk factor for vertebral fracture
Abstract
Context: Primary aldosteronism (PA) is known to increase vertebral fracture (VF), although the detailed mechanism remains to be elucidated. We hypothesized that the PA subtype is associated with VF.
Objective: To evaluate whether unilateral PA is associated with the prevalence of VF.
Design: This was a retrospective cross-sectional study in a single referral centre.
Patients: We identified 210 hypertensive patients whose clinical data were available for case-detection results. One hundred and fifty-two patients were diagnosed with PA using captopril challenge tests.
Measurements: We measured the prevalence of VF, according to PA subtype.
Results: One hundred thirteen patients with PA were subtype classified by adrenal vein sampling. Of these, 37 patients had unilateral PA, 76 patients had bilateral PA, 58 patients had non-PA; 39 patients with PA were not subtype-classified. Patients with PA had a higher prevalence of VF (29%, 44/152) than those with non-PA (12%, 7/58; P = .011). Moreover, unilateral PA had a higher prevalence of VF (46%, 17/37) than bilateral PA (20%, 15/76; P = .021). There was no significant difference in the prevalence of VF between bilateral PA and non-PA. Unilateral PA was an independent risk factor for VF after adjusting for age and sex (OR: 3.16, 95% confidence interval: 1.12-8.92; P = .017). Among patients with unilateral PA, serum cortisol concentrations after 1-mg dexamethasone suppression test were higher in those with VF (1.32 ± 0.67 g/dL) than those without (0.96 ± 0.33 g/dL; P = .048).
Conclusions: Unilateral PA is an independent risk factor for VF.
Keywords: osteoporosis; unilateral primary aldosteronism; vertebral fracture.
© 2019 John Wiley & Sons Ltd.
References
REFERENCES
-
- Mulatero P, Stowasser M, Loh K-C, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-1050.
-
- Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811-1820.
-
- Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300.
-
- Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285:126-148.
-
- Akasaka H, Yamamoto K, Rakugi H, et al. Sex difference in the association between subtype distribution and age at diagnosis in patients with primary aldosteronism. Hypertension. 2019;74(2):368-374.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
